Mr. Paul Simmons reports
INTELGENX ANNOUNCES SETTLEMENT OF U.S. PATENT LITIGATION RELATED TO FORFIVO XL(R)
IntelGenx
Technologies Corp. has
settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx's
Forfivo XL 450-milligram tablets.
The company will hold a call to discuss details of the
settlement on Wednesday, Dec. 3, 2014, at 10 a.m. ET. A live broadcast of
the call will be available through the company's website.
Following the live call, a replay will be available on the company's website,
under investor relations.
Conference dial-in: 877-269-7756
International dial-in:
201-689-7817
Conference call name: IntelGenx management update call
© 2024 Canjex Publishing Ltd. All rights reserved.